ASTRAZENAstraZeneca Pharma India Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 1.1 this quarter.
Momentum from moving averages, Supertrend and RSI.
2 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
2 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹729 Cr | ₹62 Cr | 12.37% | 8.55% | ₹24.93 | 47.8x |
| Q1 FY2027 | ₹683 Cr | ₹38 Cr | 6.40% | 5.56% | ₹15.17 | 27.0x |
| Q4 FY2026 | ₹579 Cr | ₹45 Cr | 9.56% | 7.76% | ₹17.95 | 29.5x |
| Q3 FY2026 | ₹612 Cr | ₹33 Cr | 6.70% | 5.33% | ₹13.04 | 44.9x |
| Q2 FY2026 | ₹559 Cr | ₹54 Cr | 12.99% | 9.70% | ₹21.69 | 109.7x |
| Q1 FY2026 | ₹526 Cr | ₹56 Cr | 12.26% | 10.61% | ₹22.33 | 104.8x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.